Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01688492 · ClinicalTrials.gov registry record · Phase 1

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

A Phase 1 study of Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 1
Development phase
54
Enrollment target
3
Study locations

NCT01688492: Active Phase 1 study of Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT01688492 is a Phase 1 study of Prostate Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 54 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01688492, a Phase 1 study of Prostate Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
54 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to find out what effects, good and/or bad, taking ipilimumab with abiraterone acetate plus prednisone has on the patient and the prostate cancer. Abiraterone acetate plus prednisone are drugs that lower testosterone (testosterone stimulates prostate cancer growth). Abiraterone acetate plus prednisone is a treatment for patients with prostate cancer. Abiraterone acetate plus prednisone has not been used together with ipilimumab before. This study will test how they work together. Each patient will receive abiraterone acetate, prednisone and ipilimumab.

Conditions Studied

Prostate Cancer

Interventions

  • DRUG Ipilimumab

Study Locations (3)

Illinois

  • Northwestern University - Evanston

New York

  • Memorial Sloan Kettering Cancer Center - New York

Oregon

  • Oregon Health & Science University - Portland

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2012-09
Est. Completion 2026-09
Phase Phase 1

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01688492

The ClinicalTrials.gov registry entry for NCT01688492 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Ipilimumab is the first listed.

NCT01688492 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Illinois, New York, Oregon.

Frequently Asked Questions

What is clinical trial NCT01688492 about?

NCT01688492 is a clinical study titled "Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer". The purpose of this study is to find out what effects, good and/or bad, taking ipilimumab with abiraterone acetate plus prednisone has on the patient and the prostate cancer. Abiraterone acetate plus prednisone are drugs that lower testosterone (testosterone stimulates prostate cancer growth). Abira...

What is the current status of trial NCT01688492?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2012-09. Estimated completion is 2026-09.

What conditions does trial NCT01688492 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT01688492?

The interventions under investigation include: Ipilimumab (DRUG).

Who is sponsoring clinical trial NCT01688492?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01688492 being conducted?

This trial has 3 study locations across Illinois, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.